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Abstract
Dysregulation of PKCe is involved in several serious diseases such as cancer, type II diabetes and Alzheimer’s disease.
Therefore, specific activators and inhibitors of PKCe hold promise as future therapeutics, in addition to being useful in
research into PKCe regulated pathways. We have previously described llama single chain antibodies (VHHs) that specifically
activate (A10, C1 and D1) or inhibit (E6 and G8) human recombinant PKCe. Here we report a thorough kinetic analysis of
these VHHs. The inhibiting VHHs act as non-competitive inhibitors of PKCe activity, whereas the activating VHHs have
several different modes of action, either increasing Vmax and/or decreasing Km values. We also show that the binding of the
VHHs to PKCe is conformation-dependent, rendering the determination of affinities difficult. Apparent affinities are in the
micromolar range based on surface plasmon resonance studies. Furthermore, the VHHs have no effect on the activity of rat
PKCe nor can they bind the rat form of the protein in immunoprecipitation studies despite the 98% identity between the
human and rat PKCe proteins. Finally, we show for the first time that the VHHs can influence PKCe function also in cells,
since an activating VHH increases the rate of PKCe translocation in response to PMA in HeLa cells, whereas an inhibiting VHH
slows down the translocation. These results give insight into the mechanisms of PKCe activity modulation and highlight the
importance of protein conformation on VHH binding.
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Introduction
Protein kinase C (PKC) is a family of serine/threonine kinases
that regulate several signaling pathways in cells. The ten PKC
isozymes have distinct biological functions and are divided into
three groups based on cofactor requirements [1]. All of the PKC
isozymes are regulated by phosphatidylserine (PS). In addition,
conventional PKCs (a, bI, bII and c) are activated by Ca
2+ and
diacylglycerol (DAG), novel PKCs (d, e, g and h) require only
DAG for activation, and atypical PKCs (f and i/l) are insensitive
to both DAG and Ca
2+ [2]. Conventional and novel PKC
isozymes translocate to the plasma membrane when DAG or its
surrogate, phorbol 12-myristate 13-acetate (PMA), which is often
used as a PKC activator in cellular assays, become available [3]. In
addition to cofactor binding, PKC activity is also regulated by
priming phosphorylations of three conserved phosphorylation
motifs [1] and protein-protein interactions such as binding to
receptors for activated C kinase (RACKs) [4].
PKCe plays essential roles in a variety of signaling systems
including those regulating proliferation, differentiation, gene
expression, metabolism, transport, and muscle contraction [5].
Therefore, it is not surprising that its dysregulation is implicated as
a player in several serious diseases including cancer [6,7], diabetes
mellitus [8,9] and Alzheimer’s disease [10].
In cancer, PKCe is considered a transforming oncogene that
can contribute to malignancy either by enhancing cell proliferation
or by inhibiting cell death [6]. PKCe has been found to be
overexpressed in tumor-derived cell lines and in tumor specimens
from various organ sites, and is considered to be the PKC isozyme
with the greatest oncogenic potential [11]. Furthermore, in vitro
studies have shown that overexpression of PKCe increases
proliferation, motility and invasion of fibroblasts or immortalized
epithelial cell lines [7]. One of the mechanisms by which PKCe
controls cell division is through its role in cytokinesis. PKCe
associates with 14-3-3 scaffold proteins to regulate abscission, a
process which requires PKCe kinase activity [12].
In type II diabetes, PKCe has been identified as one of the
proteins involved in insulin resistance [13]. Activated PKCe
reduces the insulin receptor (IR) gene promoter activation,
decreasing the number of IR’s on the cell surface, thereby leading
to a decrease in insulin sensitivity [8]. The decrease in IR numbers
on the cell surface is mediated by the transcription factor
HMGA1, which is inhibited from binding to the IR promoter
by a phosphorylation catalyzed by PKCe [8,14].
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fatty acid derivatives DCP-LA and DHA-CP6, have been found to
reduce amyloid b levels by enhancing the degradation of amyloid
precursor protein (APP) [15], whereas overexpression of APP in
turn decreases the levels of both membrane-bound active PKCe
and cytosolic inactive PKCe in three different cell lines [16].
Moreover, overexpression of constitutively active PKCe leads to
increased secretion of the neuroprotective peptide sAPP, which is
cleaved from APP by a-secretase [17]. Preliminary animal studies
support the role of PKCe in Alzheimer’s disease, since PKCe
activation in a transgenic mouse strain containing familial AD
mutations was found to prevent amyloid plaques, synaptic loss and
cognitive deficits [18].
PKCe is considered a desirable drug target for the treatment of
cancer, AD and diabetes among other diseases. However, since
different PKC isozymes can have different or even opposing roles
in the same process [19], any therapeutic agents would have to be
PKCe isozyme specific in order to have the desired therapeutic
effect. The group of Dr. Mochly-Rosen has described the
identification and characterization of a PKCe translocation
inhibitor (eV1-2) [20] and a PKCe agonist peptide (yeRACK)
derived from the PKCe RACK [21]. Furthermore, they have
shown that other peptides derived from the C2 domain of PKCe
have the potential to act as PKCe agonists or antagonists [22].
We have previously reported the selection and screening of
another class of PKCe specific activators and inhibitors, namely
VHHs [23]. VHHs are the antigen binding regions of llama single
chain antibodies that contain three complementary determining
regions (CDRs) involved in antigen binding [24]. VHHs are highly
soluble and stable, antigen-specific, and easy to produce [25].
They tend to have nanomolar affinities to their target antigens,
and VHHs with affinities even in the picomolar range have been
described [24]. Due to their unique structure, VHHs can also
recognize conformational epitopes such as enzyme active sites that
cannot be recognized by conventional antibodies. Furthermore,
especially the long CRD3 loops of VHHs could serve as perfect
leads for the design of new peptide drugs against various enzymes
[25]. These advantages of VHHs compared to conventional
antibodies, together with the positive data from the first clinical
trials carried out with VHHs, indicate that VHHs are promising
therapeutics, which will undoubtedly contribute to medicine in the
future [26].
Here we report further details of the PKCe specific VHH
activators (A10, C1 and D1) and inhibitors (E6 and G8) described
previously [23]. Based on surface plasmon resonance (SPR)
studies, the three activators and two inhibitors have affinities in
the micromolar range. Furthermore, we show that the VHHs
display species specificity since they do not bind the rat PKCe
despite the 98% identity between the human and rat proteins.
These VHHs were also tested in kinase activity assays to determine
the Michaelis-Menten kinetics of activation or inhibition. Finally,
we show that the VHHs have an effect on PKCe activity in a
cellular context, since the activator A10 increases both the rate
and degree of PKCe translocation in response to PMA stimulation
in HeLa cells, whereas the inhibitor G8 slows down PKCe
translocation. The results presented here give insight into the
mechanisms of PKCe activation or inhibition by VHHs and
highlight the conformation specific nature of the binding between
these VHHs and their target protein. Moreover, the results
demonstrate that these VHHs expressed inside HeLa cells as
intrabodies have the ability to influence PKCe translocation, a step
that is required for PKCe activation.
Results
Affinity measurements using Surface Plasmon Resonance
We have already shown by immunoprecipitation (IP) and kinase
activity assays that the VHH activators and inhibitors of PKCe
bind the human PKCe protein [23]. In the present study we
further characterized the VHHs by determining their affinities to
PKCe. Therefore, affinity measurements with surface plasmon
resonance (SPR) technology were performed. First, we tried to
determine the affinities using Biacore SPR technology (GE
Healthcare, UK), which is commonly used to study the
interactions of VHHs and their antigens [27–29]. A CM5 chip
was coated with human recombinant PKCe using standard
amino-coupling, and binding of VHHs to PKCe was studied in
a Biacore T100 instrument. None of the tested VHHs bound to
PKCe in this setup (data not shown). Next, each VHH was amino-
coupled to the surface of a CM5 chip and the binding of PKCe to
the flow cell surface was studied. This setup also failed, since PKCe
bound to the surface of the reference flow cell as well as the VHH-
coated flow cells (data not shown). These results were in strong
contrast to the enzyme-linked immunosorbent assay (ELISA) and
IP results described previously [23].
The Bionavis SPR Navi 200-equipment was then used to study
binding affinities. When PKCe was amino-coupled to the surface
of the flow cell, none of the VHHs showed binding to PKCe,a s
was the case with Biacore. However, when the dextran hydrogel
was amine-functionalized using ethylene diamine and PKCe was
carboxyl-coupled to the surface of the flow cell, VHH binding to
PKCe was detected (figures 1 and 2). The VHHs were injected in
serial dilutions with five different concentrations for every VHH.
The middle concentration was injected twice and served as an
internal control. The resulting data was analyzed with Trace-
Drawer 1.3 from Bionavis.
The binding of VHHs A10, C1, D1 and E6 to PKCe was best
fitted with second order Langmuir binding models based on the
forms of the binding curves. Therefore, two association constants
(ka values), two dissociation constants (kd values) and two affinities
(KD values) were calculated for each of these VHHs. The most
likely explanation for the second order models is that PKCe was
present in two or more different conformations on the surface of
the flow cell, and binding of the VHHs to two of these
conformations, with the strongest interaction affinities to VHHs,
could be detected. An alternative explanation is that the VHH
samples contained two different proteins that bound PKCe, but
this is highly unlikely since the purity of the VHH samples was
always checked on a Coomassie stained protein gel and found to
be over 95% (data not shown). The G8 data was fitted with a first
order Langmuir model, resulting in single ka,k d and KD values for
this VHH.
Out of the activators (A10, C1 and D1), C1 had the highest
affinities for PKCe coupled to the surface of the flow cell (figure 1B
and table 1), namely 3.38 mM and 7.3 mM. D1 had affinities of
44.2 mM and 7.91 mM (figure 1C and table 1) and ranked second
in affinity among the PKCe activating VHHs. A10 had the lowest
affinities of the three activators (25.4 mM and 104 mM; figure 1A
and table 1). In kinase activity assays, C1 caused the greatest
increase in PKCe activity, followed by D1 and A10 [23]. Since C1
had both the highest affinity of the three activators and led to the
greatest increase in PKCe activity, followed by D1 and A10, the
affinities measured here for the three activators support the results
from kinase activity assays.
Of the two inhibitors (E6 and G8), E6 (figure 2A) was a better
binder of PKCe immobilized to the flow cell surface than G8
PKCe Activating and Inhibiting VHHs
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587 nM and 9.71 mM, whereas the KD value for G8 was
calculated to be 102 mM (table 1). As was the case with the
activators, the obtained affinity constants support the results from
kinase activity assays, where E6 is a more potent inhibitor of
PKCe than G8 [23].
Species specificity of PKCe activating and inhibiting VHHs
We have previously shown that VHHs A10, C1 and D1
increase human recombinant PKCe kinase activity, whereas
VHHs E6 and G8 decrease kinase activity [23]. Rat brain extract
is often used as an alternative source of PKC for experiments such
as kinase activity assays, since it is known to contain many of the
PKC isozymes, including PKCe [30,31]. However, when kinase
activity assays with the VHH activators and inhibitors of PKCe
were performed using rat brain extract, no effect on kinase activity
was seen (data not shown), even though based on Western blotting
PKCe was present in the rat brain extract (figure 3A). The most
likely explanation for this is that the VHHs do not bind the rat
PKCe protein.
All of the VHHs that have been shown to have an effect on
human PKCe kinase activity are able to immunoprecipitate
human recombinant PKCe from Sf9 cell lysate [23]. To test
whether the VHHs can also bind the rat PKCe protein despite the
fact that they cannot influence its kinase activity, IPs were
performed with rat brain extract. In addition, an IP with a
commercial anti-PKCe antibody known to bind the rat form of the
protein was included as a control. The five VHHs and the
commercial anti-PKCe antibody were successfully captured by
protein A beads (figure 3B). However, rat PKCe was only
Figure 1. SPR sensograms and fits for PKCe activating VHHs.
SPR sensograms and fits for second-order Langmuir binding models are
shown for VHHs A10 (A), C1 (B) and D1 (C). The VHH injection time was
3 min, followed by a dissociation time of 5 min. The surface was
regenerated with an injection of 10 mM NaOH for 3 min, followed by a
stabilization time of 5 min between each VHH injection. Five
concentrations of each VHH were used, with the middle concentration
injected twice as an internal control. The VHH concentrations (in mg/ml)
are marked adjacent to each fit on the right hand side of the figure.
doi:10.1371/journal.pone.0035630.g001
Figure 2. SPR sensograms and fits for PKCe inhibiting VHHs.
SPR sensograms and fits for a second-order Langmuir binding model of
VHH E6 (A) and a first-order Langmuir binding model of VHH G8 (B). The
VHH injection time was 3 min, followed by a dissociation time of 5 min.
The surface was regenerated with an injection of 10 mM NaOH for
3 min, followed by a stabilization time of 5 min between each VHH
injection. Five concentrations of each VHH were used, with the middle
concentration injected twice as an internal control. The VHH
concentrations (in mg/ml) are marked adjacent to each fit on the right
hand side of the figure.
doi:10.1371/journal.pone.0035630.g002
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not by any of the VHHs. Therefore, the VHH activators and
inhibitors of PKCe do not bind the rat PKCe protein, and hence
cannot have an effect on its kinase activity. These results suggest
that the VHHs are species-specific towards human PKCe, and
confirm the very high specificity of the VHHs to human PKCe
versus other PKC isozymes, an issue which could be a concern
with peptide and other small molecule activators or inhibitors.
Kinetic measurements of PKCe activation and inhibition
To characterize the kinetics of PKCe activation or inhibition by
VHHs, kinase activity assays were performed with varying
concentrations of the substrate peptide. The VHH concentration
was kept constant (1 mg/well) for each experiment. When substrate
concentrations are varied, the resulting data can be used to
calculate the Michaelis-Menten kinetics of the activation or
inhibition.
Results from the PKCe kinase activity assay with PKCe
activators PS and 1,2-dioctanoyl-sn-glycerol (DOG; a DAG
analogue) show that the three VHHs that act as PKCe activators
have different mechanisms of activation (figure 4A and table 2).
VHH A10 leads to increased PKCe activation by almost doubling
the Vmax value, or the maximum rate achieved by the system
(141 nmol/min/mg for control and 253 nmol/min/mg for A10),
whereas it has almost no effect on the Km value of the reaction
(figure 4A). In contrast, VHHs C1 and D1 have a much smaller
effect on the Vmax, but they decrease the Km value of the system
from 424 mM for the control, to 81 mM for C1 and 126 mM for
D1. A lower Km value indicates that the reaction is faster relative
to the Vmax, so C1 and D1 seem to increase the speed of the
reaction instead of the maximum rate of the reaction. Since the
Km value is influenced both by the affinity of the enzyme to the
substrate and the rate at which the substrate bound to the enzyme
is converted to the product, the lower Km value measured with
VHHs C1 and D1 could indicate either an increase in the affinity
or the rate at which the substrate is converted to the product.
The results for the activators were similar for the kinase activity
assay that was performed with full-length PKCe without activators
PS and DOG (figure 4B). Since VHHs A10, C1 and D1 have no
effect or a very small effect on the activity of the catalytic domain
alone [23], the Michaelis-Menten kinetics of the activators on the
catalytic domain were not determined.
Based on the Michaelis-Menten constants obtained for the two
PKCe inhibiting VHHs E6 and G8, VHH E6 is a more efficient
inhibitor of PKCe than G8 is. In the assay using the full-length
PKCe protein with the activators DOG and PS present (figure 5A
and table 2), E6 decreases the Vmax from 141 nmol/min/mg
(control) to 29 nmol/min/mg, whereas G8 leads to a more
moderate decrease (Vmax of 113 nmol/min/mg).
When the PKCe activators DOG and PS are not included in
the assay (figure 5B), the difference between E6 and G8 is less and
even G8 decreases the Vmax by almost half. When the catalytic
domain of PKCe is used instead of the full-length protein
(figure 5C), the inhibition of kinase activity by E6 is so great that
the Km value cannot be reliably measured. In this case, E6
decreases the Vmax from 120 nmol/min/mg to 6.7 nmol/min/
mg. G8 is also a more potent inhibitor of the catalytic domain than
the full-length protein, since it decreases the Vmax of the reaction
almost 3-fold.
Analysis of PKCe inhibition by VHHs E6 and G8
The mechanism of PKCe inhibition by VHHs E6 and G8 was
studied with kinase activity assays with varying substrate and VHH
concentrations. We have previously shown that the binding site of
both E6 and G8 is in the catalytic domain of PKCe [23].
Therefore, Sf9 lysate expressing the catalytic domain of PKCe was
used for these assays.
The data from these assays was analyzed using non-linear
regression models but is represented as a Lineweaver-Burk plot to
allow for easy visualization of the Km and Vmax values. As can be
seen from figure 6, with both VHHs the Km of the reaction
remains about the same when the VHH concentration increases.
However, the Vmax decreases as the VHH E6 or G8 concentration
increases. In the controls without VHH, the Vmax is 46.7 nmol/
min/mg, whereas at the highest VHH concentrations used in this
Table 1. Association and dissociation constants for the interaction of VHHs with PKCe obtained from SPR measurements.
VHH ka 1 (1/(M*s)) kd 1( 1 / s ) K D 1( M ) k a 2 (1/(M*s)) kd 2 (1/s) KD 2( M )
A10 2.95610
1 (64.31610
2) 7.50610
24 (67.62610
25) 2.54610
25 (61.76610
26) 1.01610
3 (61.98610
3) 1.05610
21 (63.27610
26) 1.04E610
24 (67.21610
25)
C1 3.09610
2 (61.60610
2) 1.04610
23 (63.56610
25) 3.38610
26 (62.56610
26) 1.12610
4 (64.11610
3) 8.21610
22 (64.10610
26) 7.30610
26 (63.08610
26)
D1 2.41610
1 (62.89610
21) 1.07610
23 (62.00610
24) 4.42610
25 (68.80610
26) 5.51610
3 (61.27) 4.35610
22 (69.02610
25) 7.91610
26 (61.82610
28)
E6 5.22610
2 (62.30610
2) 3.06610
24 (66.60610
25) 5.87610
27 (64.78610
27) 1.53610
3 (64.59610
3) 1.49610
22 (65.10610
26) 9.71610
26 (63.64610
26)
G8 1.11610
1 (67.11610
2) 1.13610
23 (64.01610
25) 1.02610
24 (61.58610
26) n/a n/a n/a
doi:10.1371/journal.pone.0035630.t001
Figure 3. PKCe in rat brain extract. (A) 15 mg of rat brain extract was
separated on a SDS-PAGE gel. PKCe was detected with anti-PKCe and
HRP-conjugated goat anti-mouse antibodies. (B) Immunoprecipitations
were performed with rat brain extract using a commercial anti-PKCe
antibody (IgG Ab) and VHHs. PKCe (marked with an arrowhead) is visible
at 90 kDa on lane 1. The bands at 55 kDa and 25 kDa on lane 1
represent the heavy and light chains of the anti-PKCe antibody. The
bands at 16 kDa for A10, C1, D1, E6 and G8 represent the VHHs. A
sample of uncoated protein A sepharose beads was included as a
negative control (lane 2=ctrl).
doi:10.1371/journal.pone.0035630.g003
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and 15.9 nmol/min/mg for G8 (figure 6B).
According to the Michaelis-Menten kinetics, when the apparent
Km remains about the same but the Vmax decreases with
increasing inhibitor concentrations, the inhibition is non-compet-
itive [32]. Therefore, E6 and G8 appear to be non-competitive
inhibitors of PKCe that do not compete with the substrate peptide
MARCKS for binding to PKCe.
Effect of activator A10 and inhibitor G8 on PKCe
translocation
PKCe is known to translocate to the cell membrane in response
to PMA stimulation [3,33]. In order to study whether the VHHs
have an effect on the translocation of PKCe, one of the activating
VHHs (A10) and one of the inhibiting VHHs (G8) were cloned to
a mammalian expression vector and a C-terminal mCherry-tag
was introduced to the sequence. HeLa cells were then double-
transfected with PKCe-EGFP and the A10-mCherry or G8-
mCherry plasmids, or an mCherry control plasmid. Translocation
studies were performed with a confocal microscope 24 hours after
transfections by stimulating cells with 100 nM PMA and
monitoring the cellular localization of PKCe-EGFP and mCherry
constructs for 30 minutes.
In cells transfected with the mCherry control plasmid, about
70% of PKCe-EGFP remained in the cytoplasm 10 minutes after
PMA stimulation (figure 7A and D). Strikingly, in cells transfected
with the PKCe activator A10-mCherry, only 50% of PKCe-EGFP
was still present in the cytoplasm at this time point (figure 7B and
D). In contrast, in cells transfected with the PKCe inhibitor G8-
mCherry, 90% of PKCe-EGFP was still present in the cytoplasm
of the cells 10 minutes after PMA stimulation (figure 7C–D).
After 20 minutes, about 55% of PKCe-EGFP was present in the
cytoplasm in mCherry transfected control cells. The amount of
green fluorescence remained constant in the cytoplasm after this
time point (figure 7A and D). In cells transfected with A10-
mCherry, only about 40% of PKCe-EGFP was present in the
cytoplasm 20 minutes after PMA stimulation. As was the case with
the mCherry control transfected cells, the amount of fluorescence
in the cytoplasm remained at the same level from 20 to 30 minutes
in A10-mCherry transfected cells (figure 7B and D). In cells
transfected with G8-mCherry, 70% of PKCe-EGFP remained in
the cytoplasm of the cells at 20 minutes after PMA stimulation. In
these cells, more PKCe-EGFP translocated to the membranes
during the last 10 minutes of the experiments, since at the end of
30 minutes around 55% of PKCe-EGFP remained in the
cytoplasm of G8-mCherry transfected cells (figure 7C–D). Even
though a clear difference in translocation speed could be seen
between mCherry transfected control cells and cells transfected
with the PKCe inhibitor G8-mCherry, this difference did not
reach statistical significance at any of the time points. The
difference in PKCe-EGFP translocation between control cells
transfected with mCherry and A10-mCherry transfected cells
reached statistical significance at 20 and 30 minutes after PMA
stimulation. Therefore, the PKCe activator A10 increases both the
rate and the extent of PMA-induced PKCe translocation in HeLa
cells, whereas the inhibitor G8 slows down the rate of PKCe
translocation from the cytoplasm to the membranes.
Figure 4. Kinetics of PKCe activation by VHHs A10, C1 and D1. The kinase activity of full-length PKCe in the presence (A) and absence (B) of
PKC activators DOG and PS was measured with varying MARCKS substrate concentrations. The VHH concentration was constant (1 mg/well) for each
experiment. The data is presented as percentage maximal control activity (control activity with 1000 mM substrate) 6 SEM and represents at least 3
independent experiments, each with duplicates. Note that the Vmax values for the VHHs have not been reached yet, see table 2 for analysis.
doi:10.1371/journal.pone.0035630.g004
Table 2. Km and Vmax values for PKCe activating and inhibiting VHHs.
PKCe with activators PS and DOG (n$3) PKCe without activators PS and DOG (n$3) Catalytic domain (n$2)
Km (mM) Vmax Km (mM) Vmax Km (mM) Vmax
Control 424 141 449 139 130 120
A10 348 253 352 263 no effect no effect
C1 81 191 105 139 no effect no effect
D1 126 158 137 208 no effect no effect
E6 17 29 5.1 24 n/a 6.7
G8 260 113 121 71 158 43
doi:10.1371/journal.pone.0035630.t002
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VHH antibodies generally have affinities comparable to those of
conventional antibody fragments, with KD values in the
nanomolar range [25], and VHHs with affinity constants as low
as 100 pM have been described [24]. The high affinities displayed
by most VHHs are one of the main advantages of VHH antibodies
in research and drug development. However, here we report
affinity constants for PKCe activating and inhibiting VHHs
ranging from 587 nM to 104 mM.
One reason for the relatively low affinities described here could
be the fact that only one round of VHH selections was carried out
to obtain PKCe binders [23]. However, selections were done from
an immune VHH library and usually antigen affinities of VHHs
from immunized libraries are 10–100 times better than the
affinities of VHHs isolated from naı ¨ve or synthetic libraries [25].
Another factor that probably contributes to the relatively low
KD values is the fact that these VHHs can only bind the native
form of PKCe. The VHHs can bind human PKCe in
immunoprecipitations and kinase activity assays, but not in
Western blots where the PKCe protein has been denatured [23].
Furthermore, the VHHs tested here show relatively weak binding
in VHH ELISAs (Summanen et al., unpublished results), where
PKCe has been coated on the wells of 96-well plates.
Assays such as ELISA and SPR, where the antigen has to be
immobilized on a surface in order to measure an interaction, can
Figure 5. Kinetics of PKCe inhibition by VHHs E6 and G8. (A–B) The kinase activity of full-length PKCe in the presence (A) and absence (B) of
PKC activators DOG and PS was measured with varying MARCKS substrate concentrations. (C) The kinase activity of the catalytic domain of PKCe was
measured with varying MARCKS substrate concentrations. The VHH concentration was constant (1 mg/well) for each experiment. The data is
presented as percentage maximal control activity (control activity with 1000 mM substrate) 6 SEM and represents at least 3 independent
experiments, each with duplicates. The catalytic domain activity (C) with G8 is an exception with only 2 independent experiments with duplicates.
doi:10.1371/journal.pone.0035630.g005
Figure 6. E6 and G8 are non-competitive inhibitors of PKCe. The activity of the catalytic domain of PKCe was measured with varying MARCKS
substrate concentrations and varying concentrations of VHHs E6 (A) and G8 (B). The data was analyzed using non-linear regression and the Michaelis-
Menten kinetics model and represents 3 independent experiments, each with duplicates. The data is presented as a Lineweaver-Burk plot to allow for
the easy visualization of Km and Vmax values.
doi:10.1371/journal.pone.0035630.g006
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35630be problematic when conformation dependent interactions are
studied [34]. When the protein is immobilized using functional
groups such as 2NH2 or 2COOH groups, the protein molecules
are randomly oriented on the surface [35]. Therefore, only some
of the protein molecules will be present in an orientation that can
be recognized by the interaction partner, in this case the VHHs.
Furthermore, when the interaction between randomly immobi-
lized protein and the surface is too strong, there is a possibility of
protein denaturation [35].
Since the affinities of the five VHHs studied here could not be
measured at all with Biacore or Bionavis SPR when PKCe was
amino-coupled to the chip, it is clear that the orientation of PKCe
in the chip is crucial for measuring binding. Binding was observed
when PKCe was carboxyl-coupled instead, but also in this case
only some of the coated PKCe molecules would have been in the
correct orientation and conformation. The critical role of protein
orientation in SPR measurements is emphasized by the finding
that oriented immobilization of an antibody increased its
immunobinding efficacy approximately two-fold compared to
standard amino-coupling [36]. Therefore, the best option would
have been to immobilize PKCe to the flow cell in a controlled
Figure 7. Activator A10 increases and inhibitor G8 decreases the rate of PMA-induced PKCe-EGFP translocation in HeLa cells. (A–C)
Representative images of HeLa cells transfected with PKCe-EGFP and mCherry (A), A10-mCherry (B) or G8-mCherry (C) taken with a confocal
microscope at 1, 10, 20 and 30 minutes after adding 100 nM PMA. (D) Quantification of PKCe-EGFP translocation from the cytoplasm over time. Data
is presented as percentage relative fluorescence in the cytoplasm of cells 6 SEM from at least 2 independent experiments with 4–6 cells per
experiment (mCherry n=4, A10-mCherry n=3, G8-mCherry n=2). The difference between cells transfected with the mCherry control plasmid and
cells transfected with A10-mCherry was statistically significant (p,0.05) at 20 and 30 minutes (denoted with *).
doi:10.1371/journal.pone.0035630.g007
PKCe Activating and Inhibiting VHHs
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35630orientation via for example a His-tag [35,37], but due to technical
restrictions we were not able to perform such measurements.
As the interaction between the VHHs and PKCe seems to be
conformation dependent, the affinity constants measured here are
not likely to be the absolute affinities of these VHHs to PKCe in
the solution phase. The reported KD values should therefore not
be compared to the affinities reported for VHH antibodies
elsewhere. However, the obtained affinity constants can be used
for internal comparison to determine which PKCe binders display
the strongest interaction to PKCe. The scientific value of the KD’s
reported here is evident from the fact that the affinities do support
the data obtained from other experimental setups. Particularly,
VHH C1, the strongest activator of PKCe, also has the strongest
affinity for PKCe among the three activating VHHs. Furthermore,
E6, which is a more potent inhibitor of PKCe kinase activity than
G8, also has a higher affinity for PKCe than G8.
We also showed that in addition to the VHHs being
conformation dependent, they seem to be species-specific as well.
While all five VHHs bind human PKCe and either increase or
decrease its kinase activity, they have no effect on the kinase
activity of rat PKCe, nor did they bind it in an IP. Both human
and rat (Rattus norwegicus) PKCe proteins are 737 amino acids in
length, and identical for 726 of these amino acids (98%). Within
the catalytic domain, where all of the VHHs described here bind
to, the human and rat proteins differ in only eight amino acids.
One would expect PKCe specific antibodies to bind to both
proteins since the differences between them are so small. However,
as reported here, the VHHs do not bind rat PKCe, which again
demonstrates how subtle differences in amino acid composition or
protein conformation play a critical role in the binding of these
PKCe activating and inhibiting VHHs. Further mapping of the
VHH binding site will show if the observed species specificity is
due to a specific amino acid substitution or a small conformational
difference between the human and rat proteins.
The kinetics of the PKCe activation and inhibition were also
studied in more detail. We show here that the three activators A10,
C1 and D1 increase PKCe activity in different ways. A10 nearly
doubles the maximum rate of the reaction, whereas C1 and D1
have almost no effect on the Vmax but increase the speed of the
reaction relative to the Vmax, as is evident from the smaller Km
values reported for these VHHs. These results were similar with
and without the PKC activators DOG and PS present in the assay.
We know from previous studies [23] that all of the activating
VHHs bind the catalytic domain of PKCe. Since the VHHs can
increase PKCe kinase activity in an in vitro assay without any
additional proteins present, it seems likely that the VHH binding
somehow stabilizes the active conformation of PKCe. In order to
determine the method of PKCe activation for each VHH, the
exact binding sites for each VHH must be studied.
There are also differences between the two PKCe inhibiting
VHHs E6 and G8. Based on the kinase activity assay results
reported here, E6 is a more potent inhibitor of PKCe, since it leads
to a larger decrease in the maximum rate of the reaction. With
full-length PKCe, the Vmax is only around 20% of the control with
E6, whereas G8 has a much smaller effect on full-length PKCe
activity. When the catalytic domain is used instead of the full-
length protein, G8 also displays a larger degree of inhibition. This
supports previous results [23], where G8 was found to be a better
inhibitor of the catalytic domain alone than the full-length protein,
possibly because in the full-length protein, the G8 binding site
could be partially concealed.
According to Michaelis-Menten kinetics, both E6 and G8 are
non-competitive inhibitors of PKCe, since increasing VHH
concentrations had no effect on the apparent Km of the system
but demonstrated clear decreases in Vmax. Therefore, we can rule
out the substrate-binding site from the possible binding sites of E6
and G8 within the catalytic domain of PKCe. However, as is the
case with the activating VHHs, there are several possible
mechanisms by which E6 and G8 can have an effect on PKCe
kinase activity. A more detailed explanation of PKCe inhibition
warrants a study into the exact binding sites of E6 and G8 in the
catalytic domain of PKCe.
Remarkably, we also demonstrated for the first time that the
PKCe activating and inhibiting VHHs can influence PKCe
activity when expressed inside HeLa cells. Upon PMA stimulation,
PKCe translocates from the cytoplasm to the plasma membrane,
as was shown with EGFP-tagged PKCe in HeLa cells. The
activating VHH A10 expressed inside HeLa cells with a C-
terminal mCherry-tag increased both the rate and the degree of
PKCe translocation compared to the control. On the other hand,
the inhibiting VHH G8 decreased the rate of PKCe translocation
in response to PMA. Since PKCe translocation is required for
activation, we can conclude that the VHHs can influence PKCe
activity also in a cellular context. These results highlight the
potential of activity modulating VHHs in PKCe research and drug
development. Furthermore, the observed cellular effects suggest
that the affinities of the VHHs to PKCe are in fact better than the
micromolar affinities obtained from SPR experiments. Inside cells,
both PKCe and the VHHs will be properly folded, allowing the
VHHs to bind to their conformational epitopes on PKCe surface.
The results described here provide important additional
information about the VHH activators and inhibitors of PKCe.
In addition to the peptide-based PKCe agonists and translocation
antagonists [20,21], these VHHs are the only strictly PKCe
isozyme specific activators and inhibitors described so far. Since
the different PKC isozymes can have overlapping and sometimes
even opposing roles in many biological processes, such isozyme
specific compounds that influence kinase activity are crucial in
studying the role of PKCe in various contexts. Furthermore,
PKCe specific VHHs could in the future be developed into
therapeutics against diseases such as cancer or type II diabetes, or
the CDR regions of VHHs could be used to design novel peptide-
based therapies against these life-threatening diseases.
Materials and Methods
Materials
Mercaptoundecanol, epichlorohydrin, dextran (500 kDa from
Leuconostoc spp.), bromoacetic adid, N-ethyl-N9-(dimethylamino-
propyl) carbodiimide (EDC), N-hydroxysuccinimide (NHS), phos-
phate buffered saline (PBS) tablets, and ethanoldiamine were all
obtained from Sigma Aldrich (St. Louis, MO). Gold-coated SPR
sensor slides were obtained from BioNavis Ltd (Tampere,
Finland).
Production and purification of VHHs
Monoclonal VHH antibodies were produced and purified as
previously described [23]. Briefly, VHH production in E. coli
JM109-strain was induced by the addition of 1 mM isopropyl b-D-
1-thiogalactopyranoside (IPTG) overnight at 30uC. Periplasmic
fractions were prepared by freezing the bacterial cell pellets for 1 h
at 280uC to break the outer membrane of E. coli and resuspending
cells in 10 ml of phosphate buffered saline (PBS), followed by
mixing for 2 h at 4uC. VHHs were purified from the periplasmic
fraction using the his-tag and Talon Metal Affinity Resin
(Clontech, CA) and eluted with 300 mM imidazole. Eluted VHHs
were dialysed against PBS overnight at 4uC and stored at 220uC
until used.
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Human full-length PKCe and its catalytic domain (amino acids
298–737) were produced in Sf9 cells using the baculovirus
expression system (Bac-to-Bac, Invitrogen, Carlsbad, CA). The
cloning of PKCe constructs and baculovirus stock production has
been described before [23]. For expression of recombinant PKCe,
Sf9 cells were infected with an optimized amount of baculovirus
stock and grown for 48 h at 27uC in suspension. The collected
cells were washed with PBS and frozen until used. Crude cell
lysates were prepared by resuspending cells in lysis buffer
containing 25 mM Tris-HCl, pH 7.5, 0.5 mM EGTA and 0.1%
Triton X-100, supplemented with a protease inhibitor cocktail
(Complete, Roche, Basel, Switzerland) and centrifuging for 15 min
at 4uC at 16.200 g. Protein concentrations of the supernatants
were determined by Bradford assay (Sigma-Aldrich, St. Louis,
MO) and used for kinase activity assays as described below.
Surface Plasmon Resonance
The affinity measurements were performed with BioNavis SPR
Navi 200 (BioNavis Ltd, Tampere, Finland). Carboxymethylated
dextran hydrogel for ligand immobilization was self-synthesized
according to the BioNavis protocol. First a self-assembled
monolayer of mercaptoundecanol was formed on clean gold-
coated SPR sensor slides in an overnight reaction in ethanol and
rinsed thoroughly. The sensor was then left to react for 3 h with
epichlorohydrin (2% v/v) in 0.1 M NaOH, whereafter it was
rinsed with Milli-Q H2O, transferred to 30 g/l solution of dextran
in 0.1 M NaOH and left to react for 24 h. After washing
thoroughly with Milli-Q H2O the sensor was immersed in 0.5 M
bromoacetic acid in 2 M NaOH for 24 h. After this reaction the
sensor was thoroughly washed with Milli-Q H2O and stored at
+8uC until used in protein immobilization reaction.
Protein immobilization to the hydrogel was performed with
reverse activated ester synthesis according to the BioNavis
protocol. In brief, the immobilization was performed in situ in
the instrument using Sigma’s PBS (0.01 M phosphate buffer,
2.7 mM KCl and 137 mM NaCl, pH 7.4) as background and
injection buffer. A flow rate of 20 ml/min and an injection time of
8 min was used for all injections. Reference surface was created in
flow channel 2 in parallel with the protein immobilization. The
channel was treated in exactly the same manner as the sample
channel, except that instead of PKCe protein blank PBS was
injected.
The flow cell surface was cleaned with an injection of a solution
containing 2 M NaCl and 10 mM NaOH. Activation of the
surface was performed by an injection of a solution consisting of
200 mM EDC and 50 mM NHS. Ethylene diamine (10 mg/ml)
was injected in order to amine-functionalize the dextran hydrogel.
PKCe was diluted to 10,5 mg/ml with the EDC/NHS activation
solution, mixed well and immediately injected to the instrument.
Protein immobilization of approximately 80 pg/mm
2 was ob-
served.
The experiments were performed in HBS (Hepes buffered
saline; 20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA,
0.001% Tween-20) measurement buffer, with a temperature of
21uC and a flow rate of 20 ml/min with 8 min injection times.
Serial dilutions of the VHHs (A10 and C1: 5 mg/ml to 80 mg/ml;
D1 and E6: 6.25 mg/ml to 100 mg/ml; G8: 12.5 mg/ml to 200 mg/
ml) were injected, as is required for kinetic analysis of molecular
interactions [38]. NaOH (10 mM) was found to be an effective
regeneration agent for the system, and was used as regeneration
solution between each consecutive injection.
Rat brain extract preparation
Two rats were asphyxiated with CO2 gas and then decapitated.
The skulls were cut open and the brain tissue was scraped into ice
cold PBS. The brain tissue was then homogenized with Dounce
tissue homogenizer in buffer containing 10 mM HEPES pH 7.5
and 2 mM EDTA. The homogenized tissue was centrifuged at
1000 g for 10 min at 4uC. The resulting supernatant was
centrifuged further for 1 h at 40 000 g at 4uC. The extract was
then poured into an ion exchange column containing diethylami-
noethyl cellulose (DEAE) in column equalization buffer (10 mM
HEPES pH 7.5, 2 mM EGTA and 2 mM EDTA). The column
containing the extract was extensively washed with column
equalization buffer and the remaining bound proteins were
subsequently eluted with buffer containing 10 mM HEPES
pH 7.5, 2 mM EGTA, 2 mM EDTA, 200 mM NaCl, and
10 mM b-mercaptoethanol. The eluted protein fractions were
combined and the protein content was determined. The brain
extract was stored at 220uC after addition of 50% glycerol (final
concentration).
Western blots
To confirm the presence of PKCe in rat brain extract, 15 mgo f
protein from rat brain extract was separated by SDS-PAGE gels
and blotted onto a PVDF-membrane. The blot was probed with
1:1000 dilution of mouse anti-PKCe antibody (BD Biosciences,
NJ), followed by a 1:4000 dilution of HRP-conjugated goat anti-
mouse antibody (Santa Cruz Biotechnology, CA).
Immunoprecipitations of PKCe from rat brain extract
Immunoprecipitations (IPs) were done to check whether the
VHHs can bind the rat PKCe protein. IPs were started by
incubating 30 ml of Protein A sepharose CL-4B beads (GE
Healthcare, United Kingdom) washed once with immunoprecip-
itation buffer (IPB; 25 mM Tris-HCl pH 7.5, 0.1% Triton X-100)
with 3 mg of VHH in 1 ml of IPB for 1 h at 4uC with continuous
shaking. Simultaneously, a sample of protein A sepharose was also
coated with 1 mg of commercial PKCe antibody (BD Biosciences,
NJ) in 1 ml IPB and was used as a positive control. The antibody-
coated protein A beads were blocked with 1% BSA in IPB for
15 min at 4uC and washed once with IPB. Rat brain extract
(200 mg/sample) was added to the beads and incubated overnight
with continuous shaking at 4uC. The beads were washed 4 times
with IPB and resuspended in 15 mlo f2 6Laemmli sample buffer.
Samples were loaded onto 15% SDS-PAGE gels for separation of
proteins, electrotransferred to PDVF membranes and the
membranes were then incubated with anti-PKCe (BD Biosciences,
NJ) or anti-tetra His (Qiagen, Venlo, the Netherlands) antibodies
followed by HRP-conjugated anti-mouse antibodies (Santa Cruz
Biotechnology, CA).
Kinase activity assays
Kinase activity assays were carried out as described before [23].
Briefly, kinase activity was determined by measuring the
incorporation of [c-
32P] into a PKC substrate peptide MARCKS
(FKKSFKL). For determining Km and Vmax values, 5 mgo f
protein from Sf9 cell lysate expressing full-length PKCe or PKCe
catalytic domain was pre-incubated with 1 mg of VHH and the
substrate (0 mM–1000 mM) in a total volume of 25 ml for 10 min at
30uC in a 96-well plate. Reaction mix (75 ml/well) was added,
yielding final concentrations of 10 mM HEPES pH 7.5, 7 mM
MgCl2, 0.25 mM EGTA, 100 mM cold ATP and 0.3 mM
[c-
32P]ATP. Activity of the full-length PKCe was measured with
and without PKC activators phosphatidylserine (40 mg/ml) and
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performed for 5 min at 30uC, after which 25 ml/well was pipetted
to a P81 cation exchange paper (Whatman, Kent, United
Kingdom). The papers were washed with 75 mM phosphoric
acid, dried and placed in scintillation tubes with scintillation fluid.
Radioactivity was measured by liquid scintillation counting (1414
Winspectral, Wallac, Finland). For the analysis of PKCe inhibition
by E6 and G8, the assay was performed in the same way, except
that only the catalytic domain of PKCe was used and VHH
concentrations/well ranged from 20–161 nM (E6) and 21–
668 nM (G8). Rat brain extract (1 mg/well) was used as an
alternative source of PKCe.
Cloning of VHH-mCherry constructs and purification of
plasmid DNA
The activator A10 and the inhibitor G8 were cloned into the
pcDNA3.1+ mammalian expression vector (Invitrogen, Carlsbad,
CA) with a C-terminal mCherry tag. The mCherry plasmid was a
generous gift from Prof. Roger Tsien (University of California, San
Diego, CA). First, the mCherry-sequence was cloned into the
pcDNA3.1+ vector using the BamHI and EcoRI restriction sites.
The resulting mCherry-pcDNA3.1+ plasmid was verified by
sequencing.
The cDNA for the VHHs was PCR amplified from Pax50
bacterial expression vectors using the forward primer 59-
GGCGCTAGCATGGCAGAGGTGCAG-39 and the reverse
primer 59-GGCAGATCTCCCGTGATGGTGATG-39 to intro-
duce the NheI and BglII restriction sites. The His6-tag that was on
the C-terminus of the VHHs on the Pax50 expression vector was
included in the cloning, so that the His6-tag is situated between the
VHH and mCherry on the pcDNA3.1+ expression vector. The
PCR amplified VHH fragments were digested with NheI and BglII
and cloned into the mCherry-pcDNA3.1+ expression vector using
the NheI and BamHI sites (BglII and BamHI have complementary
sticky ends). The resulting VHH-His6-mCherry constructs were
verified by sequencing and the plasmids were produced in the E.
coli strain JM109.
Plasmid DNA for mammalian cell transfections was purified
from E. coli cells using the PureYield
TM Plasmid Midiprep System
(Promega, Fitchburg, WI). To improve the purity of the eluted
DNA, a subsequent ethanol precipitation step was performed and
the dried DNA was diluted in TE buffer. The plasmid DNA was
diluted to a concentration of 1 mg/ml and stored at 220uC. The
PKCe-EGFP plasmid, which was a kind gift from Prof. Peter
Parker (Cancer Research UK, London Research Institute), was
produced and purified as described above.
Cell culture
Human cervical cancer HeLa cells (CCL-2) were obtained from
the American Type Culture Collection (ATCC, Manassas, VA)
and cultured in DMEM supplemented with 10% fetal bovine
serum (FBS). For transfections and treatments, DMEM without
FBS was used. Cultures were incubated at 37uC in a humidified
atmosphere of 5% carbon dioxide (CO2).
HeLa cell transfections and translocation studies
For transfections, HeLa cells were seeded to 6-well plates
(350 000 cells/well in 2 ml of FBS-supplemented DMEM) and
incubated overnight to allow attachment. Double transfections of
PKCe-EGFP and mCherry, A10-mCherry or G8-mCherry were
carried out in serum-free medium with the FuGENE HD
transfection reagent (Roche, Penzberg, Germany) according to
the manufacturer’s instructions. Translocation studies were
performed at 37uC with a Leica SP2 AOBS confocal laser
scanning microscope 24 hours after transfections. Double trans-
fected cells expressing both fluorescent proteins were chosen for
the experiments, and the 488 nm argon ion laser and the 561 nm
He-Ne laser were used for the detection of EGFP-tagged PKCe
and VHH-mCherry constructs, respectively. Typically the trans-
location of PKCe-EGFP was monitored in approximately 4–6 cells
per experiment. Once double-transfected cells were located under
the microscope, 100 nM PMA was carefully added to the cells.
Images from the same cells were taken for 30 min every 30 sec.
Translocation of PKCe-EGFP after PMA addition was quantified
by measuring the relative fluorescence intensity in a region of
interest with a diameter of 5 mm placed in the cytoplasm of each
cell.
Statistical analysis
SPR kinetic analysis of the results was performed with
TraceDrawer 1.3 for BioNavis Ltd (Tampere, Finland). The
measurements were double referenced, meaning that each sample
was referenced using a blank reference channel on line and also 0-
samples were measured and referenced from all sensograms during
data analysis. Double referencing is a common procedure in SPR
biosensor experiments [38]. The sensograms were fitted with
either first order or, when appropriate, second order Langmuir
binding models in the TraceDrawer software.
The data from kinase activity assays was analyzed and
Michaelis-Menten kinetics were calculated with GraphPad Prism
4 (GraphPad Software Inc., La Jolla, CA) software using non-
linear regression. The translocation of PKCe-EGFP in HeLa cells
was quantified using Leica confocal LAS AF Lite software (Leica
Microsystems, Wetzlar, Germany). The statistical significances in
translocation speed in cells transfected with the mCherry and
VHH-mCherry constructs were calculated with SPSS 15.0
software (SPSS Inc., Chicago, IL, USA) using a one-way Anova
with Dunnett’s post-test. Statistical significance was denoted with *
when p,0.05.
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